Brief: Dynavax Initiates Phase 1/2 Study Of Novel Shingles Vaccine Program
27/06/2024 21:31
Dynavax Technologies Corp DVAX.O :
* DYNAVAX INITIATES PHASE 1/2 STUDY OF NOVEL SHINGLES
VACCINE
PROGRAM
* DYNAVAX TECHNOLOGIES CORP: ANTICIPATES REPORTING TOP LINE
IMMUNOGENICITY AND SAFETY DATA IN SECOND HALF OF 2025
Source text for Eikon: ID:nPn9BdW50a
Further company coverage: DVAX.O
Recent news on Dynavax Technologies
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
OneSpaWorld jumps as co poised to join S&P SmallCap index
Sanofi targets high single digit sales growth in 2026, plans share buyback (updated)
Focus: Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality